At JBR Pharma, we are leading the fight against autoimmune diseases with new orally available medicines targeting novel inflammatory pathways. There are over 80 autoimmune diseases such as lupus and colitis along with many inflammatory conditions like asthma and granulomatus disease that are significant unmet medical needs. Our proprietary compounds and technology were developed at and licensed from the University of Michigan and have been validated in leading preclinical models of immune diseases.